RT Journal Article T1 European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. A1 Bataller, Alex A1 Garrido, Ana A1 Guijarro, Francesca A1 Oñate, Guadalupe A1 Diaz-Beyá, Marina A1 Arnan, Montserrat A1 Tormo, Mar A1 Vives, Susana A1 de Llano, María Paz Queipo A1 Coll, Rosa A1 Gallardo, David A1 Vall-Llovera, Ferran A1 Escoda, Lourdes A1 Garcia-Guiñon, Antonio A1 Salamero, Olga A1 Sampol, Antònia A1 Merchan, Brayan M A1 Bargay, Joan A1 Castaño-Díez, Sandra A1 Esteban, Daniel A1 Oliver-Caldés, Aina A1 Rivero, Andrea A1 Mozas, Pablo A1 López-Guerra, Mònica A1 Pratcorona, Marta A1 Zamora, Lurdes A1 Costa, Dolors A1 Rozman, Maria A1 Nomdedéu, Josep F A1 Colomer, Dolors A1 Brunet, Salut A1 Sierra, Jorge A1 Esteve, Jordi AB The 2017 European LeukemiaNet (ELN 2017) guidelines for the diagnosis and management of acute myeloid leukemia (AML) have become fundamental guidelines to assess the prognosis and postremission therapy of patients. However, they have been retrospectively validated in few studies with patients included in different treatment protocols. We analyzed 861 patients included in the Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias-12 risk-adapted protocol, which indicates cytarabine-based consolidation for patients allocated to the ELN 2017 favorable-risk group, whereas it recommends allogeneic stem cell transplantation (alloSCT) as a postremission strategy for the ELN 2017 intermediate- and adverse-risk groups. We retrospectively classified patients according to the ELN 2017, with 327 (48%), 109 (16%), and 245 (36%) patients allocated to the favorable-, intermediate-, and adverse-risk group, respectively. The 2- and 5-year overall survival (OS) rates were 77% and 70% for favorable-risk patients, 52% and 46% for intermediate-risk patients, and 33% and 23% for adverse-risk patients, respectively. Furthermore, we identified a subgroup of patients within the adverse group (inv(3)/t(3;3), complex karyotype, and/or TP53 mutation/17p abnormality) with a particularly poor outcome, with a 2-year OS of 15%. Our study validates the ELN 2017 risk stratification in a large cohort of patients treated with an ELN-2017 risk-adapted protocol based on alloSCT after remission for nonfavorable ELN subgroups and identifies a genetic subset with a very poor outcome that warrants investigation of novel strategies. YR 2022 FD 2022 LK http://hdl.handle.net/10668/20248 UL http://hdl.handle.net/10668/20248 LA en DS RISalud RD Jul 29, 2025